PepEvolutionQuick answer: “Thymosin beta-4” is the full 43-amino-acid protein that almost all of the wound-healing research actually studied. “TB-500,” when a doping lab opened a real vial, turned out to be a 7-amino-acid fragment of that protein (Ac-LKKTETQ). They share one active site, so they are related. They are not the same molecule, and the fragment does not automatically inherit the protein’s human data just by borrowing its name.
Vendors and recovery forums use TB-500 and thymosin beta-4 as if they were two names for one vial. This is an evidence and naming explainer, not a protocol. Educational only: not medical advice, not dosing guidance, and not a recommendation to use either compound.
At a glance
| Thymosin β4 (Tβ4) | TB-500 (as sold) | |
|---|---|---|
| Size | 43 amino acids, ~5 kDa | 7 amino acids (Ac-LKKTETQ) |
| What it is | The full natural protein | The central actin-binding fragment of it |
| Active sites | Several: Ac-SDKP (anti-fibrotic), a survival domain, and the LKKTETQ actin motif | Only the LKKTETQ actin/angiogenesis motif |
| Human/clinical data | Rodent wound models plus small Phase 2 ulcer trials | None specific to the fragment |
| WADA status | Prohibited at all times (S2.3) | Prohibited at all times (S2.3, named as a derivative) |
The parent molecule is 43 amino acids
Thymosin β4 (Tβ4) is a small, ubiquitous peptide: 43 amino acids, about 5 kDa. It is the main G-actin sequestering peptide in mammalian cells. In plain terms, it holds a ready pool of unpolymerized actin so cells can crawl, change shape, and move into a wound (Philp et al., 2003).
That cytoskeletal job is why Tβ4 shows up in repair conversations. For a broader map of how signaling peptides work, start with Peptides 101.
Tβ4 is not a single-button peptide. Gabriel Sosne, Allan Goldstein, and colleagues showed that different stretches of the same 43-mer do different jobs (Sosne et al., 2010):
- The N-terminal tetrapeptide Ac-SDKP generally dampens inflammation and reduces fibrosis.
- A longer N-terminal stretch that includes Ac-SDKP supports cell survival and blocks apoptosis.
- The central actin-binding motif LKKTETQ (residues 17 to 23) drives angiogenesis, wound closure, and cell migration.
Keep only the middle seven residues and you keep one active site. You throw the others away.
What “TB-500” actually was when a lab opened the vial
In 2012, the Ghent University doping-control lab bought a product sold as TB-500 and identified the contents by high-resolution mass spectrometry. The peptide in the bottle was Ac-LKKTETQ: the N-acetylated 17 to 23 fragment of human Tβ4, not the intact 43-mer (Esposito et al., 2012). They synthesized that heptapeptide, confirmed the match, and built a plasma and urine detection method around it.
That paper is the closest thing the field has to a chemical definition of commercial TB-500. WADA’s 2026 Prohibited List lists both under S2.3: “Thymosin-β4 and its derivatives e.g. TB-500,” prohibited at all times (WADA, 2026). Tested athletes do not get a free pass because a vendor used a different name.
Catalogs still blur the labels. Some vials marked TB-500 are the heptapeptide. Some listings use TB-500, TB4, and thymosin beta-4 interchangeably for the full chain. Identity is a COA question, not a marketing question. If you evaluate any of these products, start with how to read a peptide COA.
The fragment is not inert, and it is not the whole protein
Philp, Huff, Hannappel, and Kleinman cut Tβ4 into pieces and tested which stretch actually made endothelial cells migrate and vessels sprout. The seven-amino-acid actin-binding motif was essential. In HUVEC migration and chick aortic-arch assays, Tβ4 and that motif showed near-identical activity around 50 nM. Peptides missing any part of the actin motif were inactive. Soluble actin blocked adhesion and sprouting, exactly what you would expect if the peptide is working through that binding site (Philp et al., 2003).
So the enthusiast claim that “TB-500 is the active part” is not invented from nothing. The angiogenic, migration-promoting pharmacophore really does sit in LKKTETQ.
The mistake is treating that as a complete substitute. Sosne’s map is the other half of the sentence. Full-length Tβ4 also carries Ac-SDKP and the survival domain, and those activities were never shown to live in the heptapeptide. A fragment that crawls cells toward a wound is not automatically a fragment that also limits fibrosis or apoptosis. Related is not interchangeable.
The human data belongs to full-length Tβ4
The animal and clinical papers people cite when they talk about TB-500 almost always used the intact protein.
- Rodent wounds. In a rat full-thickness wound model, topical or intraperitoneal Tβ4 increased re-epithelialization 42% over saline at day 4 and as much as 61% at day 7, with more collagen deposition and angiogenesis in treated wounds (Malinda et al., 1999).
- Human ulcers. Two Phase 2 trials of topical Tβ4 in pressure ulcers and venous stasis ulcers found faster closure, by almost a month, in the patients who did heal (Treadwell et al., 2012). Those were small, dose-ranging studies of the 43-mer, not randomized proof that a research-chemical fragment recreates the same curve.
There is no equivalent Phase 2 literature for Ac-LKKTETQ in human wounds. The parent peptide has a real, if still early, clinical trail. The catalog fragment has a doping-lab identity and a mechanistic claim about actin. Stacking TB-500 with BPC-157 is a forum habit, not a trial design. We covered that pairing as recovery culture in Peptides for Recovery: BPC-157 and TB-500.
What enthusiasts usually get wrong
The vial is not the paper. Citing Treadwell or Malinda while injecting a heptapeptide is a category error. Check the sequence on the COA. If it is seven residues, it is not the molecule those patients received.
Systemic distribution is a story, not a measurement. People claim the fragment “travels better” because it is smaller. That is plausible pharmacokinetics, not a published human ADME comparison against 43-mer Tβ4.
WADA does not care about the branding. Full Tβ4 and TB-500 are named together. Tested sport is not the place to litigate fragments.
Research-grade is not a wound drug. The ulcer trials used pharmaceutical topical Tβ4 under ethics approval. Lyophilized research material is a different universe. Reconstitution math lives on the calculator and in the reconstitution guide. Neither is a prescription.
Where this sits in 2026
Tβ4 is one of the better-mapped repair peptides in cell biology. The actin site, the N-terminal anti-fibrotic tetrapeptide, the rodent wound work, and the Phase 2 ulcer signals are real. What is not real is a large outpatient evidence base for unsupervised “TB-500 cycles,” or a demonstration that the seven-mer equals the 43-mer in people.
If you are comparing sources, use identity and purity the same way you would for any other compound. The provider directory and price index exist for that comparison, not as a shopping list. For clinicians and researchers who talk about repair peptides at the protein-domain level rather than forum shorthand, see the experts page.
Bottom line
Thymosin beta-4 is a 43-amino-acid actin-sequestering protein with several active sites. TB-500, when a lab actually characterized it, was the acetylated LKKTETQ fragment of that protein. The fragment can carry the angiogenic motif. It does not carry the rest of the molecule, and it does not inherit the human wound-trial data by renaming. If a listing treats them as synonyms, the listing is the thing to distrust.